(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Well informed: How to Take full advantage of Your Gadgets - 2Little Urban areas to Visit in Western Europe
- 3Home Wellness Basics: Building Your Home Exercise center
- 4A Gastronomic Experience in Healthy Enjoyments: A Survey of \Nutritious and Tasty\ Solid Cooking Recipe Book
- 5Pacific voyagers’ remarkable environmental knowledge allowed for long-distance navigation without Western technology
- Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- Innospace's rocket crashes in first commercial launch in Brazil; shares tumble
- U.S. overhauls childhood vaccine schedule, recommends fewer shots
- Voting begins in Uganda’s presidential election during internet shutdown and polling station delays
- The Best Internet based Retailers for Style and Frill
- Step by step instructions to Look at Compact disc Rates: A Thorough Aide
- Europe picks companies to help build Argonaut moon lander
- Culinary Joys: Investigating Connoisseur Cooking at Home
